Loxo Oncology Inc (NASDAQ:LOXO) dropped 6.3% during trading on Tuesday . The company traded as low as $133.06 and last traded at $133.45. Approximately 735,175 shares traded hands during trading, an increase of 81% from the average daily volume of 406,540 shares. The stock had previously closed at $142.45.

LOXO has been the topic of a number of analyst reports. Cann reaffirmed a “buy” rating and set a $202.00 price objective on shares of Loxo Oncology in a research note on Monday, September 17th. Zacks Investment Research cut shares of Loxo Oncology from a “buy” rating to a “hold” rating in a research note on Thursday, August 16th. Citigroup dropped their price objective on shares of Loxo Oncology from $235.00 to $233.00 and set a “buy” rating on the stock in a research note on Wednesday, October 24th. Ifs Securities raised shares of Loxo Oncology from a “market perform” rating to an “outperform” rating in a research note on Monday, October 8th. Finally, Stifel Nicolaus dropped their price objective on shares of Loxo Oncology from $225.00 to $217.00 and set a “buy” rating on the stock in a research note on Friday, August 10th. Three analysts have rated the stock with a hold rating, fourteen have issued a buy rating and two have issued a strong buy rating to the company. Loxo Oncology currently has a consensus rating of “Buy” and an average price target of $189.38.

The firm has a market cap of $4.30 billion, a price-to-earnings ratio of -25.13 and a beta of 2.21.

Loxo Oncology (NASDAQ:LOXO) last announced its quarterly earnings data on Thursday, November 8th. The biopharmaceutical company reported ($0.89) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.65) by ($0.24). The firm had revenue of $42.47 million during the quarter, compared to analysts’ expectations of $38.55 million. Loxo Oncology had a negative net margin of 43.49% and a negative return on equity of 16.42%. During the same quarter in the previous year, the business posted ($2.45) EPS. As a group, analysts forecast that Loxo Oncology Inc will post -2.34 earnings per share for the current year.

In other news, CEO Joshua H. Bilenker sold 20,000 shares of Loxo Oncology stock in a transaction on Thursday, September 13th. The stock was sold at an average price of $166.20, for a total transaction of $3,324,000.00. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, VP Jennifer Burstein sold 2,500 shares of Loxo Oncology stock in a transaction on Thursday, September 13th. The stock was sold at an average price of $166.96, for a total value of $417,400.00. Following the transaction, the vice president now owns 1,250 shares in the company, valued at approximately $208,700. The disclosure for this sale can be found here. Insiders sold a total of 102,500 shares of company stock worth $16,412,950 in the last 90 days. 17.10% of the stock is currently owned by insiders.

Hedge funds and other institutional investors have recently bought and sold shares of the company. First Mercantile Trust Co. increased its position in shares of Loxo Oncology by 45.8% during the 3rd quarter. First Mercantile Trust Co. now owns 1,029 shares of the biopharmaceutical company’s stock worth $176,000 after purchasing an additional 323 shares during the last quarter. Commonwealth Equity Services LLC acquired a new stake in shares of Loxo Oncology during the 2nd quarter worth about $209,000. LPL Financial LLC acquired a new stake in shares of Loxo Oncology during the 3rd quarter worth about $244,000. Pacer Advisors Inc. acquired a new stake in shares of Loxo Oncology during the 3rd quarter worth about $255,000. Finally, Aperio Group LLC acquired a new stake in shares of Loxo Oncology during the 2nd quarter worth about $306,000. Institutional investors and hedge funds own 96.81% of the company’s stock.

WARNING: “Loxo Oncology (LOXO) Shares Down 6.3%” was first reported by Watch List News and is the property of of Watch List News. If you are accessing this news story on another publication, it was illegally copied and republished in violation of U.S. and international trademark & copyright laws. The original version of this news story can be read at https://www.watchlistnews.com/loxo-oncology-loxo-shares-down-6-3/2662610.html.

Loxo Oncology Company Profile (NASDAQ:LOXO)

Loxo Oncology, Inc, a biopharmaceutical company, develops and sells medicines for patients with genetically defined cancers in the United States. Its lead product candidate comprises larotrectinib, an oral selective inhibitor of tropomyosin receptor kinase (TRK), which is in adult Phase 1 trial, a pediatric Phase 1/2 trial, and an adult/adolescent Phase 2 trial for the treatment of patients with tumor types, such as lung, head and neck, melanoma, colorectal, sarcoma, and breast cancer.

Further Reading: Market Capitalization in the Stock Market

Receive News & Ratings for Loxo Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Loxo Oncology and related companies with MarketBeat.com's FREE daily email newsletter.